Dr. Spencer Krane is an Assistant Professor of Urology at Tulane University School of Medicine. After earning his undergraduate degree at the University of Michigan and his medical doctorate at Tulane University School of Medicine, he completed his fellowship in minimally invasive and robotic urology at Henry Ford Hospital, under the guidance of Dr. Mani Menon, the father of robotic surgery. Subsequently, he trained in regenerative medicine techniques at the Wake Forest Institute for Regenerative Medicine, completed his Urology Residency at Wake Forest Baptist Health, then received additional training in the personalized treatments for prostate and kidney cancer, including MRI fusion-guided biopsies and precision-based therapeutics, at the National Cancer Institute in Bethesda, Maryland. Dr. Krane is an author of more than 50 peer-reviewed articles published in creditable journals, he has presented his work at national and international conferences, and he has received numerous awards for his research from the American Urologic Association (AUA) for providing patients a catheter-less radical prostatectomy (2009); from the AUA for identifying which patients benefit from prostate cancer screening (2014); and from the American Society of Clinical Oncologists (ASCO) for drug repurposing in bladder cancer, based on changes in gene expression (2016).
In addition to his professorship, Dr. Krane practices as a urologic oncologist at Tulane Urology, where he offers precision-based care, minimally invasive procedures, and advanced robotic treatments, including partial nephrectomy or nephroureterectomy, for patients with prostate, kidney, and bladder cancer. A specialist in all forms of focal treatments for prostate cancer, such as cryotherapy, High Intensity Focused Ultrasound (HIFU), and irreversible electroporation (IRE), Dr. Krane tailors his care to the specific needs of each patient. Most patients are enrolled in clinic trials to ensure efficacious treatment and to continue improving the science of focal ablations, as this is an emerging field. Importantly, not all patients are candidates for focal therapy, thus Dr. Krane is comfortable recommending radical whole gland therapy (radiotherapy or radical prostatectomy) for those unlikely to benefit from focal ablation. Additionally, by using advanced transperineal biopsy technology to reach areas of the prostate poorly accessed by a transrectal approach, he can detect prostate cancer without the risks of serious infection generally associated with a transrectal approach.
Originally from New Orleans, Dr. Spencer Krane is an educated leader in “cutting-edge technology without the cut” and a charismatic physician determined to provide the best of care for all his patients. Currently accepting new patients at his clinic, Dr. Krane can be reached at 504-988-5271 for an appointment.
For more information about Dr. Spencer Krane's publications, visit PubMed.